International Society of Atopic Dermatitis Poster Presentation: Itch Reduction and Quality of Life Improvement in AD for First Human Use of Zabalafin

Clinical Presentations

International Society of Atopic Dermatitis Poster Presentation: Itch Reduction and Quality of Life Improvement in AD for First Human Use of Zabalafin NEWS PROVIDED BY Alphyn Biologics October 26, 2024, 19:30 ET N432_Neal-KOLLER_Itch-Reduction-and-Quality-of-Life-Improvement-in-AD-for-First-Human-Use-of-Zabalfin CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195

2024 European Association of Dermatology and Venerology (EADV) Poster Presentation: Itch Reduction and Quality of Life Improvement in AD for First Human Use of Zabalafin Hydrogel

Clinical Presentations

2024 European Association of Dermatology and Venerology (EADV) Poster Presentation: Itch Reduction and Quality of Life Improvement in AD for First Human Use of Zabalafin Hydrogel NEWS PROVIDED BY Alphyn Biologics September 28, 2024, 19:30 ET CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195

Alphyn to Present Poster on Zabalafin Hydrogel Clinical Results at European Academy of Dermatology and Venereology Congress 2024

Press Release

Alphyn to Present Poster on Zabalafin Hydrogel Clinical Results at European Academy of Dermatology and Venereology Congress 2024 NEWS PROVIDED BY Alphyn Biologics Aug 27, 2024, 07:30 ET ANNAPOLIS, Md., Aug. 27, 2024 /PRNewswire/ — Alphyn Biologics, Inc., a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that data from its Phase 2a human clinical…

Alphyn Receives Notice of Claims Allowance for U.S. Patent Covering Zabalafin Hydrogel

Press Release

Alphyn Receives Notice of Claims Allowance for U.S. Patent Covering Zabalafin Hydrogel NEWS PROVIDED BY Alphyn Biologics Aug 21, 2024, 07:30 ET ANNAPOLIS, Md., Aug. 21, 2024 /PRNewswire/ — Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that it has received a notice of claims allowance from the U.S. Patent and Trademark…

Society for Pediatric Dermatology Poster Presentation: First-in-Human Phase 2 Trial of Zabalafin Hydrogel (AB-101a) – Itch and Quality of Life Pediatric Results

Clinical Presentations

Society for Pediatric Dermatology Poster Presentation: First-in-Human Phase 2 Trial of Zabalafin Hydrogel (AB-101a) – Itch and Quality of Life Pediatric Results NEWS PROVIDED BY Alphyn Biologics July 8, 2024, 19:30 ET CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195